Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study
Open accessAbstract
MedDRA Medical
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Randomized clinical trial data from an open-label 5-year trial of insulin glargine versus NPH insulin did not find evidence of excess cancer risk (all sites combined) in the insulin glargine arm, although there was a very small number of cancer end points.
“Randomized clinical trial data from an open-label 5-year trial of insulin glargine versus NPH insulin did not find evidence of excess cancer risk (all sites combined) in the insulin glargine arm (118), although among the ∼1,000 subjects randomized, there was a very small number of cancer end points (57 cancer cases in the glargine arm and 62 cases in the NPH arm).”
From Diabetes and Cancer (2010) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · see citing works
Hemkens, L. G., Grouven, U., Bender, R., Günster, C., Gutschmidt, S., Selke, G. W., & Sawicki, P. T. (2009) · Diabetologia · doi:10.1007/s00125-009-1418-4 · Cited by 607 · see citing works
Jonasson, J. M., Ljung, R., Talbäck, M., Haglund, B., Gudbjörnsdòttir, S., & Steineck, G. (2009) · Diabetologia · doi:10.1007/s00125-009-1444-2 · Cited by 412 · see citing works
SDRN Epidemiology Group, & Colhoun, H. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1453-1 · Cited by 387 · see citing works
Rosenstock, J., Fonseca, V. A., McGill, J. B., Riddle, M. C., Hallé, J., HRAMIAK, I. M., Johnston, P., & Davis, J. L. (2009) · Diabetologia · doi:10.1007/s00125-009-1415-7 · Cited by 87 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366 · see citing works
Diabetes and Cancer: A Consensus Report
Giovannucci, E. L., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20078 · Cited by 1,065 · see citing works
Belfiore, A., Frasca, F., Pandini, G., Sciacca, L., & Vigneri, R. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0047 · Cited by 1,035 · see citing works
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918 · see citing works
Growth hormone, the insulin-like growth factor axis, insulin and cancer risk
Clayton, P., Banerjee, I., Murray, P. G., & Renehan, A. G. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.171 · Cited by 362 · see citing works
Diabetes and cancer: two diseases with obesity as a common risk factor
Garg, S. K., Maurer, H., Reed, K., & SELAGAMSETTY, R. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12124 · Cited by 274 · see citing works
Pharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Pοlyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. Α., Katsiki, N., UNDERWOOD, P. C., Park, K., Seufert, J., Kang, E. S., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 190 · see citing works
Yang, X., Ko, G. T. C., So, W. Y., Ronald, C. W., Yu, L. W. L., Kong, A. P. S., Zhao, H., Chow, C., Tong, P. C. Y., & Chan, J. C. N. (2010) · Diabetes · doi:10.2337/db09-1371 · Cited by 162 · see citing works
Insulin glargine and malignancy: an unwarranted alarm
Pocock, S., & Smeeth, L. L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61307-6 · Cited by 148 · see citing works
Evans, M., Schumm‐Draeger, P. ‐., Vora, J. P., & King, A. B. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01395.x · Cited by 146 · see citing works
Combined randomised controlled trial experience of malignancies in studies using insulin glargine
Home, P., & Lagarenne, P. (2009) · Diabetologia · doi:10.1007/s00125-009-1530-5 · Cited by 141 · see citing works
Karlstad, Ø., Starup‐Linde, J., Vestergaard, P., Hjellvik, V., Bazelier, M. T., Schmidt, M. K., Andersen, M., Auvinen, A. P., Haukka, J. K., Furu, K., et al. (2013) · Current Drug Safety · doi:10.2174/15680266113136660067 · Cited by 119 · see citing works
Diabetes and Cancer: Is Diabetes Causally Related to Cancer?
Suh, S., & Kim, K. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.3.193 · Cited by 118 · see citing works
Ruiter, R., Visser, L. E., van Herk‐Sukel, M. P. P., Coebergh, J. W. W., Haak, H. R., Geelhoed-Duijvestijn, P. H. L. M., Straus, S. M. J. M., Herings, R. M. C., & Stricker, B. H. C. (2011) · Diabetologia · doi:10.1007/s00125-011-2312-4 · Cited by 108 · see citing works
Blin, P., Lassalle, R., Dureau‐Pournin, C., Ambrosino, B., Bernard, M., Abouelfath, A., Gin, H., Jeunne, C. L., Pariente, A., Droz‐Perroteau, C., et al. (2012) · Diabetologia · doi:10.1007/s00125-011-2429-5 · Cited by 94 · see citing works
Further Exploration of the Relationship Between Insulin Glargine and Incident Cancer
Morden, N. E., Liu, S. K., Smith, J., MacKenzie, T. A., Skinner, J., & Korc, M. (2011) · Diabetes Care · doi:10.2337/dc11-0699 · Cited by 94 · see citing works
Latest insights into the risk of cancer in diabetes
Noto, H., Goto, A., Tsujimoto, T., Osame, K., & Noda, M. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12068 · Cited by 88 · see citing works
An injectable and glucose-sensitive nanogel for controlled insulin release
Wu, Z., Zhang, X., Guo, H., Li, C., & Yu, D. (2012) · Journal of Materials Chemistry · doi:10.1039/c2jm34082h · Cited by 87 · see citing works
Bordeleau, L. J., Yakubovich, N., Dagenais, G. R., Rosenstock, J., Probstfield, J. L., Yu, P. C., Rydén, L., Pīrāgs, V., Spinas, G. A., Birkeland, K. I., et al. (2014) · Diabetes Care · doi:10.2337/dc13-1468 · Cited by 85 · see citing works
Self-citationSemlitsch, T., Engler, J., Siebenhofer, A., Jeitler, K., Berghold, A., & Horvath, K. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005613.pub4 · Cited by 80 · see citing works
Chowdhury, T. A. (2010) · QJM · doi:10.1093/qjmed/hcq149 · Cited by 76 · see citing works
Block versus Random Amphiphilic Glycopolymer Nanopaticles as Glucose-Responsive Vehicles
Guo, Q., Zhang, T., An, J., Wu, Z., Zhao, Y., Dai, X., Zhang, X., & Li, C. (2015) · Biomacromolecules · doi:10.1021/acs.biomac.5b01020 · Cited by 75 · see citing works
Importance of Beta Cell Function for the Treatment of Type 2 Diabetes
Saisho, Y. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3030923 · Cited by 71 · see citing works
Wu, J. W., Filion, K. B., Azoulay, L., Doll, M. K., & Suissa, S. (2016) · Diabetes Care · doi:10.2337/dc15-1816 · Cited by 69 · see citing works
Diabetes mellitus: influences on cancer risk
Szablewski, L. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2573 · Cited by 67 · see citing works
Insulin – Pharmacology, Therapeutic Regimens and Principles of Intensive Insulin Therapy
Donner, T. W., & Sarkar, S. (2015) · Europe PMC (PubMed Central) · Cited by 63 · see citing works
What's fueling the biotech engine—2008
Aggarwal, S. (2009) · Nature Biotechnology · doi:10.1038/nbt1109-987 · Cited by 61 · see citing works
Does Insulin Therapy Promote, Reduce, or Have a Neutral Effect on Cancers?
Gerstein, H. C. (2010) · JAMA · doi:10.1001/jama.2010.60 · Cited by 57 · see citing works
Gu, Y., Wang, C., Zheng, Y., Hou, X., Mo, Y., Yu, W., Zhang, L., Hu, C., Nan, H., Chen, L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053411 · Cited by 55 · see citing works
Bronsveld, H. K., ter Braak, B., Karlstad, Ø., Vestergaard, P., Starup‐Linde, J., Bazelier, M. T., Bruin, M. L. D., de Boer, A., Siezen, C. L. E., van de Water, B., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0611-2 · Cited by 54 · see citing works
Chang, C., Toh, S., Lin, J., Chen, S., Kuo, C.-W., Chuang, L., & Lai, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021368 · Cited by 54 · see citing works
Diabetes and pancreatic cancer.
Muniraj, T., & Chari, S. T. (2012) · PubMed · Cited by 52 · see citing works
Diabetes, antihyperglycemic medications and cancer risk
Gallagher, E. J., & LeRoith, D. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/01.med.0000433065.16918.83 · Cited by 52 · see citing works
Cancer Risk in Type 2 Diabetes Mellitus: Metabolic Links and Therapeutic Considerations
Sun, G. E. C., & Kashyap, S. R. (2011) · Journal of Nutrition and Metabolism · doi:10.1155/2011/708183 · Cited by 51 · see citing works
Diabetes Mellitus and Increased Risk of Cancer: Focus on Metformin and the Insulin Analogs
McFarland, M. S., & Cripps, R. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.11.1159 · Cited by 50 · see citing works
Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin
Stürmer, T., Marquis, M. A., Zhou, H., Meigs, J. B., Lim, S. K., Blonde, L., MacDonald, E. B., Wang, R., LaVange, L. M., Pate, V., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0263 · Cited by 48 · see citing works
Chong, C. R., & Chabner, B. A. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0286 · Cited by 47 · see citing works
Insulins: Past, Present, and Future
Borgoño, C. A., & Zinman, B. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.03.002 · Cited by 45 · see citing works
Diabetes and cancer: Epidemiology and potential mechanisms
Joost, H. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114550813 · Cited by 45 · see citing works
Home, P. (2013) · Diabetes Care · doi:10.2337/dcs13-2002 · Cited by 44 · see citing works
Rosenstock, J., Fonseca, V. A., Schinzel, S., Dain, M., Mullins, P. R., & Riddle, M. C. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.04.003 · Cited by 42 · see citing works
Self-citationGarg, S. K. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0127 · Cited by 38 · see citing works
The metabolic and mitogenic properties of basal insulin analogues
Tennagels, N., & Ulrich, W. (2013) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2012.754474 · Cited by 38 · see citing works
Müssig, K., Staiger, H., Kantartzis, K., Fritsche, A., Kanz, L., & Häring, H. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03132.x · Cited by 37 · see citing works
Insulin Glargine and Cancer Risk in Patients with Diabetes: A Meta-Analysis
Tang, X., Yang, L., He, Z., & Liu, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051814 · Cited by 37 · see citing works
Call, R., Grimsley, M., Cadwallader, L., Cialone, L., Hill, M., Hreish, V., King, S., & Riche, D. M. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.05.2153 · Cited by 37 · see citing works
Cancer with Diabetes: Prevalence, Metabolic Control, and Survival in an Academic Oncology Practice
Karlin, N. J., Dueck, A. C., & Cook, C. B. (2012) · Endocrine Practice · doi:10.4158/ep12128.or · Cited by 37 · see citing works
Buchs, A. E., & SILVERMAN, B. G. (2011) · Metabolism · doi:10.1016/j.metabol.2011.05.002 · Cited by 34 · see citing works
Diabetes, insulin treatment, and cancer risk: what is the evidence?
Azar, M., & Lyons, T. J. (2009) · F1000 Medicine Reports · doi:10.3410/m2-4 · Cited by 31 · see citing works
Ciaraldi, T. P., & Sasaoka, T. (2010) · Hormone and Metabolic Research · doi:10.1055/s-0030-1267203 · Cited by 27 · see citing works
Antihyperglycaemic therapies and cancer risk
Lutz, S. Z., Staiger, H., Fritsche, A., & Häring, H. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114549553 · Cited by 27 · see citing works
Glucose Metabolism Disorders and the Risk of Cancer
Piątkiewicz, P., & Czech, A. (2011) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-011-0119-0 · Cited by 25 · see citing works
Synthetic Insulin Analogs and Their Use in Dogs and Cats
Gilor, C., & Graves, T. K. (2010) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2009.11.001 · Cited by 25 · see citing works
Do we have enough data to confirm the link between antidiabetic drug use and cancer development?
Drzewoski, J., Drozdowska, A., & Śliwińska, A. (2011) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.1029 · Cited by 25 · see citing works
Insulin Glargine and Risk of Cancer: A Meta-Analysis
Du, X., Zhang, R., Xue, Y., Li, D., Cai, J., Zhou, S., Huang, Z., Yu, R., & Liu, Y. (2012) · The International Journal of Biological Markers · doi:10.5301/jbm.2012.9349 · Cited by 23 · see citing works
Diabetes and cancer relationships (糖尿病与肿瘤的关联性)
Wang, T., Ning, G., & Bloomgarden, Z. T. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12057 · Cited by 21 · see citing works
Insulin glargine use and breast cancer risk: Associations with cumulative exposure
Peeters, P. J. H. L., Bazelier, M. T., Leufkens, H. G. M., Auvinen, A. P., van Staa, T. P., de Vries, F., & Bruin, M. L. D. (2016) · Acta Oncologica · doi:10.3109/0284186x.2016.1155736 · Cited by 21 · see citing works
Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes
Donner, T. W., & Joseph, J. J. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s50286 · Cited by 20 · see citing works
Insulin Therapy and Cancer in Type 2 Diabetes
Mannucci, E. (2012) · ISRN Endocrinology · doi:10.5402/2012/240634 · Cited by 20 · see citing works
Diabetes: glycaemic control in type 2 (drug treatments).
Gorter, K. J., de Laar, F. A. V., Janssen, P. G. H., Houweling, S. T., & Rutten, G. E. H. M. (2012) · Europe PMC (PubMed Central) · Cited by 19 · see citing works
Impaired Glucose Metabolism, Anti-Diabetes Medications, and Risk of Thyroid Cancer
Kushchayeva, Y. S., Kushchayev, S. V., Jensen, K. E., & Brown, R. J. (2022) · Cancers · doi:10.3390/cancers14030555 · Cited by 19 · see citing works
Diabetes and risk of tumors: oncologic considerations
Rosta, A. (2011) · Orvosi Hetilap · doi:10.1556/oh.2011.29158 · Cited by 19 · see citing works
Controversies in the use of insulin analogues
Werner, H., Weinstein, D., Yehezkel, E., & Laron, Z. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.540233 · Cited by 18 · see citing works
Cancer Specific Mortality in Insulin-Treated Type 2 Diabetes Patients
Ioacără, S., Guja, C., Ionescu-Tirgoviste, C., Fica, S. V., & Roden, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093132 · Cited by 18 · see citing works
Advances in Pharmacologic Therapies for Type 2 Diabetes
Morsink, L. M., Smits, M. M., & Diamant, M. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0302-8 · Cited by 18 · see citing works
Tabernacki, T., Wang, L., Kaelber, D. C., Xu, R., & Berger, N. A. (2024) · Cancers · doi:10.3390/cancers16132377 · Cited by 15 · see citing works
Raz, I., & Eldor, R. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2265 · Cited by 14 · see citing works
Glargine and Cancer: Can We Now Suggest Closure?
Owens, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-1968 · Cited by 14 · see citing works
Putting Insulin Glargine and Malignancies into Perspective
Ehninger, G., & Schmidt, A. H. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0206 · Cited by 13 · see citing works
Long-acting basal insulin analogs: latest developments and clinical usefulness
Mavrogiannaki, A. N., & Migdalis, I. N. (2012) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622312454158 · Cited by 13 · see citing works
The longest ever randomised controlled trial of insulin glargine: study design and HbA1c findings
Currie, C. J. (2009) · Diabetologia · doi:10.1007/s00125-009-1477-6 · Cited by 12 · see citing works
The path to approval of new drugs for diabetes
Rendell, M. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.770470 · Cited by 12 · see citing works
Detemir as a once-daily basal insulin in type 2 diabetes
Nelson (2011) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s19539 · Cited by 11 · see citing works
Looking at the carcinogenicity of human insulin analogues via the intrinsic disorder prism
Redwan, E. M. M. M., Linjawi, M. H., & Uversky, V. N. (2016) · Scientific Reports · doi:10.1038/srep23320 · Cited by 11 · see citing works
Landgraf, R., Kellerer, M., Aberle, J., Fach, E.-M., Gallwitz, B., Hamann, A., Joost, H., Klein, H., Müller‐Wieland, D., Nauck, M. A., et al. (2018) · Diabetologie und Stoffwechsel · doi:10.1055/a-0598-0475 · Cited by 11 · see citing works
Kishimoto, S., Ishihara, M., Takikawa, M., Mori, Y., Hattori, H., Fujita, M., & Nakamura, S. (2012) · Pharmaceutics · doi:10.3390/pharmaceutics4010042 · Cited by 10 · see citing works
Floch, J. P. L. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s7315 · Cited by 10 · see citing works
The Impact of Diabetes Mellitus on the Second Primary Malignancies in Colorectal Cancer Patients
Halámková, J., Kazda, T., Pehalová, L., Goněc, R., Kozáková, Š., Bohovicová, L., Slabý, O., Demlová, R., Svoboda, M., & Kišš, I. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.573394 · Cited by 9 · see citing works
Role and application of hysterosalpingography and Fallopian tube recanalization.
Mallarini, G., & Saba, L. (2010) · PubMed · Cited by 9 · see citing works
Reichstetter, S., Castillo, G. M., Lai, M., Nishimoto-Ashfield, A., Banerjee, A. A., Bogdanov, A. A., Jr., Lyubimov, A. V., & Bolotin, E. M. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0646-8 · Cited by 8 · see citing works
Diabetes, Antihyperglycemic Medications and Cancer Risk: Smoke or Fire?
Gallagher, E. J., & LeRoith, D. (2013) · Endocrine Practice · doi:10.4158/ep13190.ra · Cited by 8 · see citing works
Insulin glargine and cancer: cause and effect unproven
Owens, D. R., Rosenstock, J., & Bolli, G. B. (2009) · Practical Diabetes · doi:10.1002/pdi.1388 · Cited by 8 · see citing works
Self-citationInsufficient evaluation of adverse events is not a proof of safety
Hemkens, L. G., Grouven, U., Bender, R., & Sawicki, P. T. (2010) · Diabetologia · doi:10.1007/s00125-009-1654-7 · Cited by 8 · see citing works
Lindauer, K., Bartels, T., Scherer, P., & Kabiri, M. (2019) · Toxicologic Pathology · doi:10.1177/0192623319863129 · Cited by 7 · see citing works
Home, P., & Itzhak, B. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001077 · Cited by 7 · see citing works
Impaired glucose metabolism treatment and carcinogenesis
Matyszewski, A., Czarnecka, A. M., Kawecki, M., KORZEŃ, P., SAFIR, I. J., Kukwa, W., & Szczylik, C. A. (2015) · Oncology Letters · doi:10.3892/ol.2015.3324 · Cited by 7 · see citing works
Cancer Risk in Type 2 Diabetes
Kong, A. P. S., & Chan, J. C. N. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0277-4 · Cited by 7 · see citing works
Lim, S. K., Stember, K. G., He, W. W., Porneala, B., Yelibi, C., Marquis, A., Stürmer, T., Buse, J. B., & Meigs, J. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109433 · Cited by 7 · see citing works
Borgquist, S., Rosendahl, A. H., Czene, K., Bhoo‐Pathy, N., Dorkhan, M., Hall, P. N., & Brand, J. S. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1026-7 · Cited by 7 · see citing works
Edwards, K. L., Riche, D. M., Stroup, J. S., Goldman, J. D., Vellurattil, R. P., Cross, L. B., & Kane, M. P. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.9.955 · Cited by 6 · see citing works
Optimizing treatment strategies with insulin glargine in Type 2 diabetes
Owens, D. R. (2012) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.12.29 · Cited by 5 · see citing works
Kwak, S., Forbes, B. E., Lee, Y., Belgi, A., Wade, J. D., & Hossain, M. A. (2010) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-010-9218-8 · Cited by 5 · see citing works
India suspends pioglitazone: Is it justified?
SADIKOT, S. M., & Ghosal, S. (2014) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2013.10.020 · Cited by 5 · see citing works
Bloomgarden, Z. T. (2011) · Diabetes Care · doi:10.2337/dc11-0591 · Cited by 5 · see citing works
Análogos de insulina: modificaciones en la estructura, consecuencias moleculares y metabólicas
de Luis, D. A., & Romero, E. (2012) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2012.04.010 · Cited by 5 · see citing works
Regulatory Forum Opinion Piece
Bartels, T., Wäse, K., Heinrichs, M., Stolte, M., Roome, N. O., Scherer, P., & Lindauer, K. (2016) · Toxicologic Pathology · doi:10.1177/0192623316665721 · Cited by 5 · see citing works
The insulin glargine dilemma: an opportunity for the diabetes community?
Stümvoll, M., & Nawroth, P. P. (2009) · Diabetologia · doi:10.1007/s00125-009-1490-9 · Cited by 5 · see citing works
Potential Mechanisms Linking Insulin to Cancer
Babichev, Y., Khalid, S., & Fantus, I. G. (2011) · Energy balance and cancer · doi:10.1007/978-1-4419-9911-5_7 · Cited by 4 · see citing works
Choice of Long-Acting Insulin Therapy for Type 2 Diabetes
Krentz, A. J., & Sinclair, A. J. (2011) · Drugs & Aging · doi:10.2165/11597820-000000000-00000 · Cited by 4 · see citing works
Insulin, other hypoglycemic drugs, and glucagon
Page, R. C. L. (2011) · Side effects of drugs annual · doi:10.1016/b978-0-444-53741-6.00042-8 · Cited by 3 · see citing works
- Authors
- Rosenstock, J., Fonseca, V., McGill, J. B., Riddle, M., Hallé, J. P., Hramiak, I., Johnston, P., & Davis, M.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Tulane University (US)
- Washington University in St. Louis (US)
- Oregon Health & Science University (US)
- Université de Montréal (CA)
- Western University (CA)
- University of Wisconsin–Madison (US)
- Corresponding author
- Rosenstock, J.
- Venue
- Diabetologia
- Published
- 2009-07-16
- Volume
- 52
- Issue
- 9
- Pages
- 1971-1973
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC2723677
- OpenAlex
- W2135096382
- Cited by
- 141
- References
- 5
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 3 · 2018: 3 · 2017: 1 · 2016: 5 · 2015: 6 · 2014: 14 · 2013: 16 · 2012: 16
- FWCI
- 20.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Diabetologia (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Sanofi
- Tulane University
- McGill University
- MannKind Corporation
- Daiichi-Sankyo
- Novo Nordisk
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- insulin glargine, neutral protamine Hagedorn insulin, type 2 diabetes, cancer risk, cancer incidence, long-acting insulin, insulin analogues
- MeSH terms
- Insulin Glargine, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Humans, Hypoglycemic Agents, Insulin, Insulin, Isophane, Neoplasms, Risk Factors, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
